See more : Heads UP Ventures Limited (HEADSUP.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Sanofi (SNY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sanofi, a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
- Atico Mining Corporation (ATCMF) Income Statement Analysis – Financial Results
- DECIPHER LABS LIMITED (DECIPHER.BO) Income Statement Analysis – Financial Results
- Alimentation Couche-Tard Inc. (CJA.F) Income Statement Analysis – Financial Results
- PJSC Tatneft (ATAD.IL) Income Statement Analysis – Financial Results
- Macarthur Minerals Limited (MIO.AX) Income Statement Analysis – Financial Results
Sanofi (SNY)
About Sanofi
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 46.03B | 45.39B | 39.18B | 37.37B | 37.63B | 35.68B | 36.22B | 34.70B | 34.86B | 32.00B | 31.29B | 35.96B | 35.06B | 32.04B | 30.75B | 28.82B | 29.25B | 29.49B | 28.49B | 15.03B | 8.03B | 7.46B | 6.49B | 5.96B | 5.35B |
| Cost of Revenue | 14.24B | 13.69B | 12.26B | 12.16B | 11.98B | 11.32B | 11.45B | 10.70B | 10.92B | 10.23B | 10.29B | 11.08B | 10.90B | 8.72B | 7.88B | 7.34B | 7.58B | 7.59B | 7.56B | 3.75B | 1.43B | 1.38B | 1.25B | 1.44B | 1.49B |
| Gross Profit | 31.80B | 31.70B | 26.92B | 25.21B | 25.66B | 24.36B | 24.77B | 24.00B | 23.94B | 21.77B | 21.00B | 24.88B | 24.16B | 23.32B | 22.87B | 21.48B | 21.67B | 21.90B | 20.93B | 11.28B | 6.61B | 6.08B | 5.24B | 4.52B | 3.86B |
| Gross Profit Ratio | 69.07% | 69.83% | 68.72% | 67.47% | 68.18% | 68.27% | 68.40% | 69.16% | 68.68% | 68.03% | 67.10% | 69.20% | 68.90% | 72.79% | 74.37% | 74.55% | 74.08% | 74.27% | 73.47% | 75.05% | 82.26% | 81.50% | 80.69% | 75.82% | 72.11% |
| Research & Development | 6.73B | 6.71B | 5.69B | 5.53B | 6.02B | 6.35B | 5.57B | 5.23B | 5.08B | 4.67B | 4.61B | 4.91B | 4.81B | 4.40B | 4.58B | 4.58B | 4.54B | 4.43B | 4.04B | 7.45B | 1.31B | 1.22B | 1.03B | 945.00M | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 75.00M | 106.00M | 106.00M | 114.00M | -542.00M | -495.00M | 182.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 9.39B | 9.88B | 9.86B | 10.06B | 9.49B | 9.38B | 9.11B | 8.60B | 8.95B | 8.54B | 7.57B | 7.33B | 7.17B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 10.77B | 10.54B | 9.56B | 9.39B | 9.88B | 9.93B | 10.16B | 9.59B | 9.50B | 8.57B | 8.11B | 9.13B | 8.54B | 7.57B | 7.33B | 7.17B | 7.87B | 8.02B | 8.24B | 4.50B | 2.47B | 2.43B | 2.31B | 2.02B | 1.89B |
| Other Expenses | 6.45B | 2.57B | 2.53B | 2.40B | 2.53B | 1.70B | 1.66B | 1.65B | 2.23B | 3.02B | 3.13B | 3.02B | 3.62B | 3.58B | 3.14B | -23.00M | 3.20B | 3.45B | 2.93B | -360.73M | -246.94M | -189.64M | -208.00M | -17.00M | 995.00M |
| Operating Expenses | 23.94B | 19.81B | 17.77B | 17.32B | 18.43B | 17.99B | 17.39B | 16.48B | 16.81B | 16.25B | 15.84B | 17.05B | 16.97B | 15.55B | 15.05B | 11.72B | 15.61B | 15.90B | 15.21B | 11.59B | 3.54B | 3.46B | 3.13B | 2.94B | 2.89B |
| Cost & Expenses | 38.16B | -7.29B | 30.03B | 29.48B | 30.41B | -7.73B | -7.42B | -7.18B | -7.44B | -5.64B | -5.86B | -7.29B | 27.87B | 24.27B | 22.93B | 19.06B | 23.20B | 23.49B | 22.77B | 15.34B | 4.96B | 4.84B | 4.38B | 4.39B | 4.38B |
| Interest Income | 546.00M | 206.00M | 40.00M | 53.00M | 141.00M | 164.00M | 147.00M | 68.00M | 178.00M | 193.00M | 109.00M | 93.00M | 140.00M | 105.00M | 24.00M | 65.00M | 190.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.09B | 461.00M | 368.00M | 390.00M | 444.00M | 495.00M | 420.00M | 924.00M | 559.00M | 598.00M | 609.00M | 751.00M | 552.00M | 467.00M | 324.00M | 335.00M | 329.00M | 1.54B | 4.71B | 2.53B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 3.78B | 3.70B | 3.13B | 3.27B | 3.75B | 3.46B | 3.15B | 2.99B | -2.48B | -2.75B | -3.39B | -3.20B | 4.91B | 5.44B | 5.00B | 245.00M | 4.48B | 6.73B | 5.95B | 2.52B | 117.52M | 179.16M | 301.00M | 241.00M | 236.00M |
| EBITDA | 12.00B | 14.06B | 11.29B | 17.51B | 7.11B | 9.36B | 10.28B | 10.36B | 10.23B | 9.87B | 9.62B | 11.43B | 10.64B | 11.40B | 11.40B | 10.48B | 10.40B | 12.12B | 11.67B | 2.25B | 3.19B | 3.00B | 2.41B | 1.82B | 1.21B |
| EBITDA Ratio | 26.06% | 30.98% | 27.47% | 26.13% | 26.15% | 26.24% | 28.38% | 29.86% | 29.36% | 30.84% | 30.74% | 34.77% | 30.35% | 35.59% | 36.98% | 34.73% | 35.56% | 42.26% | 47.01% | 14.99% | 39.67% | 37.49% | 37.10% | 30.49% | 22.56% |
| Operating Income | 7.88B | 16.79B | 8.13B | 8.08B | 7.69B | 12.43B | 12.01B | 12.34B | 12.71B | 12.62B | 13.01B | 15.70B | 5.73B | 5.96B | 6.37B | 9.76B | 5.92B | 5.73B | 7.45B | -262.61M | 3.07B | 2.62B | 2.11B | 1.58B | 971.00M |
| Operating Income Ratio | 17.11% | 37.00% | 20.74% | 21.63% | 20.45% | 34.84% | 33.15% | 35.57% | 36.46% | 39.45% | 41.58% | 43.67% | 16.35% | 18.61% | 20.70% | 33.88% | 20.24% | 19.43% | 26.13% | -1.75% | 38.21% | 35.09% | 32.46% | 26.45% | 18.15% |
| Total Other Income/Expenses | -722.00M | -166.00M | -328.00M | 24.00M | -229.00M | 228.00M | -188.00M | -720.00M | -403.00M | -458.00M | -459.00M | -1.81B | -542.00M | -362.00M | -300.00M | -232.00M | -139.00M | -981.21M | -2.11B | -588.67M | 58.76M | -108.64M | 34.00M | -17.00M | -48.00M |
| Income Before Tax | 7.15B | 10.49B | 7.80B | 13.80B | 2.82B | 4.90B | 5.62B | 5.81B | 5.22B | 5.61B | 4.52B | 6.17B | 5.32B | 5.60B | 6.07B | 9.49B | 5.78B | 4.75B | 2.64B | -1.84B | 3.13B | 2.51B | 2.14B | 1.56B | 0.00 |
| Income Before Tax Ratio | 15.54% | 23.11% | 19.91% | 36.94% | 7.50% | 13.75% | 15.50% | 16.75% | 14.98% | 17.52% | 14.45% | 17.15% | 15.17% | 17.48% | 19.73% | 32.94% | 19.76% | 16.10% | 9.27% | -12.25% | 38.94% | 33.63% | 32.98% | 26.16% | 0.00% |
| Income Tax Expense | 1.60B | 2.01B | 1.56B | 1.81B | 139.00M | 481.00M | 1.72B | 1.33B | 709.00M | 1.21B | 726.00M | 1.11B | 455.00M | 1.24B | 1.36B | 2.76B | 687.93M | 800.12M | 477.04M | 818.09M | 1.06B | 747.13M | 842.00M | 611.00M | 346.00M |
| Net Income | 5.40B | 8.37B | 6.22B | 12.29B | 2.81B | 4.31B | 3.89B | 4.71B | 4.29B | 4.39B | 3.72B | 4.97B | 5.69B | 4.36B | 5.27B | 7.19B | 5.27B | 4.01B | 2.26B | -2.66B | 2.07B | 1.76B | 1.59B | 985.00M | 625.00M |
| Net Income Ratio | 11.73% | 18.44% | 15.89% | 32.90% | 7.46% | 12.07% | 10.75% | 13.57% | 12.30% | 13.72% | 11.88% | 13.81% | 16.24% | 13.60% | 17.12% | 24.94% | 18.02% | 13.58% | 7.92% | -17.70% | 25.80% | 23.61% | 24.43% | 16.52% | 11.68% |
| EPS | 4.31 | 6.69 | 4.97 | 9.81 | 2.33 | 3.45 | 3.08 | 3.42 | 3.38 | 3.25 | 2.75 | 3.70 | 4.27 | 3.34 | 4.03 | 2.94 | 3.91 | 2.97 | 1.68 | -2.92 | 2.95 | 2.42 | 2.17 | 1.35 | 0.85 |
| EPS Diluted | 4.30 | 6.66 | 4.95 | 9.76 | 2.31 | 3.43 | 3.07 | 3.39 | 3.34 | 3.21 | 2.71 | 3.68 | 4.26 | 3.33 | 4.03 | 2.94 | 3.89 | 2.95 | 1.67 | -2.91 | 2.95 | 2.42 | 2.17 | 1.35 | 0.85 |
| Weighted Avg Shares Out | 1.25B | 1.25B | 1.25B | 1.25B | 1.25B | 1.25B | 1.27B | 1.29B | 1.32B | 1.32B | 1.32B | 1.33B | 1.32B | 1.31B | 1.31B | 1.31B | 1.35B | 1.35B | 1.34B | 910.30M | 702.75M | 727.69M | 731.71M | 731.23M | 730.78M |
| Weighted Avg Shares Out (Dil) | 1.26B | 1.26B | 1.26B | 1.26B | 1.26B | 1.26B | 1.27B | 1.30B | 1.32B | 1.33B | 1.34B | 1.33B | 1.33B | 1.31B | 1.31B | 1.31B | 1.35B | 1.36B | 1.35B | 914.80M | 705.12M | 729.27M | 731.71M | 731.23M | 730.78M |
5 Large Drug Stocks to Watch From a Thriving Industry
Sanofi, GSK, CSL tapped to expand US bird flu vaccine supply, Bloomberg News reports
Recordati buys rights to rare immune disorder drug from Sanofi for $825 mln
Sanofi, Regeneron's Dupixent Gets FDA Approval for COPD
Regeneron-Sanofi Drug Wins FDA Approval To Treat COPD
FDA Approves Regeneron/Sanofi's Blockbuster Dupixent For Smoker's Lung Disease
US FDA approves Sanofi-Regeneron's Dupixent for 'smoker's lung'
Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD
Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD
Are Investors Undervaluing Sanofi (SNY) Right Now?
Source: https://incomestatements.info
Category: Stock Reports